Category: IHC-Antibodies

Name: MUM1 Antibody (Clone MUM1p)

Description and aplications: MUM1 / IRF4 is an oncogene associated with myeloma. The protein has a molecular weight of 51.6 kDa and is encoded by a gene on chromosome 6p25-p23 region located mainly in the nucleus of lymphocytes. When MUM1 is not expressed, the B / T cells do not get activated and the immunoglobulins are not secreted by the plasma cells. Most neoplasms composed of mature lymphoid cells express MUM1. Therefore, this protein is expressed in a subset of B cells in the germinal center in plasma cells and in activated T cells. MUM1 is a marker that helps in characterizing the histogenesis of lymphoma / leukemia of B origin. In Bcell lymphomas, MUM1 expression presents a predictive role of the genetic profile and represents, together with CD10 and BCL-6, the base of Hans classification for diffused large B cell lymphomas. MUM1 positivity, in these cases, suggests a non-germinal center phenotype and is predictive for prognosis, especially in pediatric cases. In Burkitt lymphomas, that shares cytological, architectural and histological aspects with some cases of DLBCL of “Burkitt-like”, the MUM1 is negative in general or positive in a small percentage of cases or tumoral cells. All cases of primary effusion lymphomas and most cases of primary brain lymphomas are MUM1 positive. Other lymphoid neoplasm express MUM1. Melanomas can also stain with MUM1.

Composition: anti-MUM1 mouse monoclonal antibody obtained from supernatant culture and prediluted in a tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Name: Lambda light chain Antibody (Clone EP172)

Description and applications: Each immunoglobulin molecule consists of two identical heavy chains and two identical light chains. There are two types of light chains designated as kappa and lambda. The gene rearrangement process that generates the immunoglobulin molecule results in either a productive kappa or lambda gene. The mechanics of the rearrangement process normally produce approximately twice as many kappa-bearing cells as lambda. However this ratio is lost during malignant transformation. The kappa light chain antibody labels kappa light chain expressing B lymphocytes and plasma cells. Other cells may also express kappa light chain due to nonspecific uptake of immunoglobulin.

Composition: anti-human Lambda light chain rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Name: Kappa light chain Antibody (Clone EP171)

Description and applications: Each immunoglobulin molecule consists of two identical heavy chains and two identical light chains. There are two types of light chains designated as kappa and lambda. The gene rearrangement process that generates the immunoglobulin molecule results in either a productive kappa or lambda gene. The mechanics of the rearrangement process normally produce approximately twice as many kappa-bearing cells as lambda. However this ratio is lost during malignant transformation. The kappa light chain antibody labels kappa light chain expressing B lymphocytes and plasma cells. Other cells may also express kappa light chain due to nonspecific uptake of immunoglobulin. Individual B cells express either kappa or lambda light chains. Monoclonality is generally assumed to be evidence of a malignant proliferation. The pairing of an antilambda with a kappa light chain antibody is useful for identifying monoclonality of lymphoid malignancies.

Composition: anti-human Kappa light chain rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

Name:Anti-human p40Rabbit Monoclonal Antibody (Clone ZR8)

Description and applications: P63 consists of two major isoforms-TAp63 and ΔNp63. These isoforms differ in the structure of the Nterminal domains. The TAp63 isoform (identified by anti-p63 antibody) contains a transactivation-competent ‘TA’ domain with homology to p53, which regulates the expression of the growth-inhibitory genes. In contrast, ΔNp63 isoform (identified by anti-p40 antibody) contains an alternative transcriptionally-inactive ‘ΔN’ domain, which antagonizes the activity of TAp63 and p53. The p40 (clone ZR8) antibody recognizes exclusively ΔNp63 but not TAp63. p40 is a squamous cell carcinoma ‘specific’ antibody. It reacts with the vast majority of cases of squamous cell carcinomas of various origins, but not with adenocarcinomas. It is particularly useful in differentiating lung squamous cell carcinoma from lung adenocarcinoma. p40 antibody can also be used as an alternative basal cell/myoepithelial cell marker, which has similar sensitivity and specificity as that of p63 antibody. Therefore, p40 antibody may also be used as an alternative immunohistochemical markerfor determining prostate adenocarcinoma vs. benign prostate glands and for determining breast intraductal carcinoma vs. invasive breast ductal carcinoma.

Composition: anti-human p40 rabbit monoclonal purified antibody in 0.2% BSA and 15mM sodium azide.

Immunogen: Synthesized polypeptides from Nterminal domain of p63.

Name: Rabbit anti-human p53 Monoclonal Antibody

Description and applications: p53 is a tumour suppressor gene expressed in a wide variety of tissue types and is involved in regulating cell growth, replication, and apoptosis. The p53 gene is located on chromosome 17p, a frequent location in the loss of alleles in many tumors such as lung, colon, breast and brain. p53 expression is associated with a poor prognosis in breast cancer. In colon tumors, the p53 protein is expressed in 47% of cancers and only 9% of adenomas. In addition, p53 mutations are associated with a large number of malignant tumors, including ovarian, bladder and melanomas.

Composition: anti-human p53 rabbit monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Immunogen: Recombinant human full length wild type p53 protein

Name: PTEN Antibody (Clone 6H2.1)

Description and aplications: The antibody recognizes a protein fraction of 403 amino acids encoded by the PTEN gene located on chromosome 10q23.3 region. PTEN protein acts as a dual specificity phosphatase. On one hand, it dephosphorylates the phosphorylated proteins in tyrosine, serine, and threonine residues and on the other hand, it acts as a lipid phosphatase removing the phosphate group of the D3 position of the inositol ring in phosphatidylinositol-3,4,5-trisphosphate, phosphatidylinositol-3,4-diphosphate, phosphatidylinositol-3-phosphate, and inositol 1,3,4,5- tetrakisfosfato. This last feature is critical to act as a tumor suppressor through the negative regulation of the signaling pathway PI3K-AKT / PKB. This latter controls cell cycle progression, the tissue development, cell migration, and inhibition of apoptosis. In this signaling pathway, PTEN antagonistic effect on PI3K-AKT / PKB also maintains the stability of p53. PTEN also controls other cell cycle proteins such as p27, p130, myc, and cyclin D1. PTEN gene mutations induce alterations in the functioning of cells in a manner that the loss of PTEN protein expression is associated with tumor genesis, cancer progression, and cancer-resistance to different
treatments. Due to its role in cell growth, the vast majority of normal tissues express high amount of the PTEN protein. The loss of PTEN protein expression was observed in some malignancies associated with abnormalities in the PTEN gene. These abnormalities
can be monoallelic (gliomas and carcinomas of breast, prostate, lung, and colon) or biallelic (endometrial carcinomas, prostate and breast cancer, or glioblastoma multiforme). There are also some genetic diseases with alterations of germinal type in the PTEN gene like Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease and a subgroup of patients with Proteus syndrome. Somatic mutations of PTEN with loss of protein expression present variable incidences although they are often observed in sporadic endometrial carcinomas and in glioblastoma multiforme. These mutations are usually related to the histological grade of the tumor and are considered poor prognostic factors. Loss of PTEN expression is also a prognostic factor in gastrointestinal stromal tumors (GIST), tumors of the salivary glands, intrahepatic cholangiocarcinoma, gallbladder carcinomas, etc. In addition to being a prognostic factor, PTEN antibody immunostaining acts as a predictive indicator of the response to therapy using chemotherapeutic agents aimed at molecular targets. Controversial results obtained with the PTEN antibody are apparently related to the antibody clone used and/or tissue fixation issues. The only clone with reproducible results in the diagnosis of paraffin embedded samples, especially in endometrial adenocarcinomas and their precursor lesions, is the 6H2.1. However, superior results are always obtained in excisional biopsy or curettage samples in comparison with immunostaining of hysterectomies samples, where fixing is usually worse. In this sense and to mitigate immunostaining loss it is recommended to use freshly obtained serial sections of the sample.

Composition: anti-PTEN mouse monoclonal antibody obtained from supernatant culture and prediluted in a tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Name: Antibody PU-1

Description and applications: This antibody recognises a protein with a molecular mass of 42 kDa corresponding to PU.1 transcription factor, a member of the Ets family of transcription factors. It is required for the normal development and maturation of multiple hematopoietic lineages. PU.1 is a transcription factor restricted to the hematopoietic system, expressed in the myeloid series and in B cells but absent in mature T cells, the erythroid series, and in non-hematopoietic cells. Among the cells of the myeloid series, PU.1 is overexpressed in monocytes, histiocytes, and dendritic cells. Nodular lymphocyte-predominant Hodgkin lymphoma is consistently positive for PU.1, as opposed to classical Hodgkin lymphoma; therefore, PU.1, along with Pax-5, Oct-1, Oct-2, and BOB.1, is useful in establishing the differential diagnosis between both entities. PU.1 transcription factor and AML1, a DNAbinding subunit of the CBF transcription factor family, act as tumour suppressors in leukaemias. The function of PU.1 is down-regulated by AML1-ETO in myeloid leukaemias, while overexpression of PU.1 restores normal differentiation. High expression of PU.1 in follicular lymphomas gives them greater survival. PU.1 is a suitable marker to identify cutaneous neoplasms originating from histiocytes or from dendritic cells (reticulohistiocytomas, Langerhans cell histiocytosis, or juvenile xanthogranulomas).Dermatofibrosarcoma protuberans, dermatofibromas, fibrous papules, Spitz nevi, and melanomas are not stained with anti-PU.1.

Composition:Anti-human PU-1 rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Intended use : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Name: Antibody Retinoblastoma clone same as Rb1) 1F8

Description and applications: Rb is a tumor suppressor nuclear phosphoprotein capable of binding to DNA. It is phosphorylated on serine and threonine, but not on tyrosine residues. It forms a complex with SV40 large T antigen, adenovirus E1A and human papilloma virus-16 E. Rb protein may act by regulating transcription and loss of its function leads to uncontrolled cell growth. 90% of neoplasias express moderately or intensely pRb (carcinomas of the breast, colon, stomach, endometrium, head and neck, lung, neuroendocrine, gliomas, lymphomas, melanoma, ovarian, pancreatic, kidney, urothelial, cutaneous and thyroid). The alteration of the Rb gene with the absence of nuclear expression of pRb has been demonstrated in some human tumors, including retinoblastoma, breast carcinoma, prostate cancer, lung cancer and some sarcomas.

Composition: Anti-human Retinoblastoma mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: Antibody S100 Protein clone 4C4.9

Description and aplications:
S100 belongs to the family of calcium binding proteins such as calmodulin and troponin C. S100A is composed of an alpha and beta chain whereas S100B is composed of two beta chains. S100 protein is also expressed in the antigen presenting cells such as the Langerhans cells in skin and interdigitating reticulum cells in the paracortex of lymph nodes. The S100 antibody staines schwannomas, ependymomas, astrogliomas, most melanomas and their metastases. It is also characteristic in adipose and chondroid tissue benign and malignant neoplasms. It can also be used as a myoepithelial marker for breast pathology diagnostic. Therefore, this antibody is useful for the identification of malignant melanomas, neuroectodermal, adipocytic and chondroid tumors. This antibody has a cross-reactivity with smooth muscle fibers that can be visible in some occasions.

Composition: anti-human S100 Mouse monoclonal antibody purified from ascites. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name: Antibody SALL4 clone EE-30

Description and aplications: Sall3 (SALL3, sal-like 3) and Sall4 (SALL4, sal-like 4) are mammalian homologs of the Drosophila region-specific homeotic gene spalt, which encodes a zinc fingercontaining transcription regulator. Drosophila spalt is an essential genetic component required for the specification of posterior head and anterior tail as opposed to trunk. Sall3 is expressed at 24 weeks of gestation in several regions of the human fetal brain including neurons of the hippocampus formation and of mediodorsal and ventrolateral thalamic nuclei, Purkinje cells of the cerebellum and a subset of neurons in the brainstem. Sall4 expression in early mouse embryos is gradually confined to the head region and the primitive streak, followed by prominent expression in the developing midbrain, branchial arches, limbs and genital papilla. SALL4 has been considered as a pan-marker for germ cell tumors. However, positivity might occur in undifferentiated neoplasm of digestive or urogenital system.

Composition: anti-human SALL4 mouse monoclonal antibody prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name:Antibody Serotonin clone 5HT-H209

Description and applications: Serotonin-positive cells are present in gastric, duodenal, jejunal, ileal, colonic, and appendiceal mucosae. Positive cells are sparse and usually occur in the lower half of the gastric and intestinal mucosae. In the appendix, in addition to the mucosal serotonincontaining cells, there are single or small clusters of serotoninpositive cells in the sub-epithelial region of the lamina propria.

Composition: Anti-human Serotonin mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Name:Antibody Skeletal Muscle Actin clone 5C5,F8,C7

Description and applications: 5C5.F8.C7 MAb is highly specific and shows no crossreaction with smooth muscle actin. This antibody reacts with sarcomeric actins of normal tissues and neoplasms derived from such tissues (i.e. rhabdomyosarcomas).

Composition: Anti-human Skeletal Muscle Actin mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide